Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Robert Nshimiyimana, Ph.D.


Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Nshimiyimana R, Glynn SJ, Serhan CN, Petasis NA. Stereocontrolled total synthesis of Resolvin D4 and 17(R)-Resolvin D4. Org Biomol Chem. 2022 Nov 08. PMID: 36345797.
    Citations:    Fields:    
  2. Hamidzadeh K, Westcott J, Wourms N, Shay AE, Panigrahy A, Martin MJ, Nshimiyimana R, Serhan CN. A newly synthesized 17-epi-NeuroProtectin D1/17-epi-Protectin D1: Authentication and functional regulation of Inflammation-Resolution. Biochem Pharmacol. 2022 09; 203:115181. PMID: 35850309; PMCID: PMC9398963.
    Citations:    Fields:    
  3. Nshimiyimana R, Lam TF, Aggarwal S, Serhan CN, Petasis NA. First stereoselective total synthesis of 4(S),5(S)-oxido-17(S)-hydroxy-6(E),8(E),10(Z),13(Z),15(E),19(Z)-docosahexaenoic acid, the biosynthetic precursor of resolvins D3 and D4. RSC Adv. 2022 Apr 13; 12(19):11613-11618. PMID: 35481084; PMCID: PMC9015894.
  4. Serhan CN, Libreros S, Nshimiyimana R. E-series resolvin metabolome, biosynthesis and critical role of stereochemistry of specialized pro-resolving mediators (SPMs) in inflammation-resolution: Preparing SPMs for long COVID-19, human clinical trials, and targeted precision nutrition. Semin Immunol. 2022 01; 59:101597. PMID: 35227568; PMCID: PMC8847098.
    Citations: 1     Fields:    
  5. Shay AE, Nshimiyimana R, Samuelsson B, Petasis NA, Haeggström JZ, Serhan CN. Human leukocytes selectively convert 4S,5S-epoxy-resolvin to resolvin D3, resolvin D4, and a cys-resolvin isomer. Proc Natl Acad Sci U S A. 2021 12 21; 118(51). PMID: 34911767; PMCID: PMC8713978.
    Citations: 2     Fields:    Translation:HumansCells
  6. Pham TL, Kakazu AH, He J, Nshimiyimana R, Petasis NA, Jun B, Bazan NG, Bazan HEP. Elucidating the structure and functions of Resolvin D6 isomers on nerve regeneration with a distinctive trigeminal transcriptome. FASEB J. 2021 08; 35(8):e21775. PMID: 34245621.
    Citations: 3     Fields:    Translation:Animals
  7. Pham TL, He J, Kakazu AH, Calandria J, Do KV, Nshimiyimana R, Lam TF, Petasis NA, Bazan HEP, Bazan NG. ELV-N32 and RvD6 isomer decrease pro-inflammatory cytokines, senescence programming, ACE2 and SARS-CoV-2-spike protein RBD binding in injured cornea. Sci Rep. 2021 06 17; 11(1):12787. PMID: 34140611.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  8. Sansbury BE, Li X, Wong B, Riley CO, Shay AE, Nshimiyimana R, Petasis NA, Serhan CN, Spite M. PCTR1 Enhances Repair and Bacterial Clearance in Skin Wounds. Am J Pathol. 2021 06; 191(6):1049-1063. PMID: 33689792; PMCID: PMC8176141.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  9. Libreros S, Shay AE, Nshimiyimana R, Fichtner D, Martin MJ, Wourms N, Serhan CN. A New E-Series Resolvin: RvE4 Stereochemistry and Function in Efferocytosis of Inflammation-Resolution. Front Immunol. 2020; 11:631319. PMID: 33643307.
    Citations: 13     Fields:    Translation:HumansCells
  10. Pham TL, He J, Kakazu AH, Calandria J, Do KV, Nshimiyimana R, Petasis NA, Bazan HEP, Bazan NG. Elovanoid-N32 or RvD6-isomer decrease ACE2 and binding of S protein RBD after injury or INF? in the eye. Res Sq. 2020 Aug 11. PMID: 32818210; PMCID: PMC7430585.
    Citations: 1     
  11. Do KV, Kautzmann MI, Jun B, Gordon WC, Nshimiyimana R, Yang R, Petasis NA, Bazan NG. Elovanoids counteract oligomeric ß-amyloid-induced gene expression and protect photoreceptors. Proc Natl Acad Sci U S A. 2019 11 26; 116(48):24317-24325. PMID: 31712409.
    Citations: 27     Fields:    Translation:HumansAnimalsCells
  12. Barnette DA, Johnson BP, Pouncey DL, Nshimiyimana R, Desrochers LP, Goodwin TE, Miller GP. Stereospecific Metabolism of R- and S-Warfarin by Human Hepatic Cytosolic Reductases. Drug Metab Dispos. 2017 09; 45(9):1000-1007. PMID: 28646078; PMCID: PMC5539582.
    Citations: 3     Fields:    Translation:HumansCells
  13. Pugh CP, Pouncey DL, Hartman JH, Nshimiyimana R, Desrochers LP, Goodwin TE, Boysen G, Miller GP. Multiple UDP-glucuronosyltransferases in human liver microsomes glucuronidate both R- and S-7-hydroxywarfarin into two metabolites. Arch Biochem Biophys. 2014 Dec 15; 564:244-53. PMID: 25447818; PMCID: PMC4258421.
    Citations: 4     Fields:    Translation:HumansCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Nshimiyimana's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (63)
Co-Authors (4)
Similar People (60)
Same Department 
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.